Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Congrats longs!! I got out a couple of weeks ago but looks like this is easily on its way to $ 6-$7
Did I miss something? I thought he was going to announce the name of the hospital and physician that treated these patients. The interview seems heavily edited, probably a good thing, lol. I'm long, hope this stock takes off even more.
I hope you are right. I sold most of my shares in early June but decided to back up the wagon again today!
GLTA
So I think there is a good chance PPHM is preparing the 'POTENTIAL' use of the ATM at higher PPS. That could point to something up-coming which they expect the pps to go up with and then do a minimum of ATM shares at high prices.
It could also point to nothing upcoming.
Perhaps they have some good news to share on Monday morning and wanted to get this out of the way first. It wouldn't be the first time.
Yep, I wish I had
There could be many reasons.
At last years ASM I remember ku asking questions regarding partnering. The answers were that things were really heating up. Then months later Steve Worsley is brought on which then leads me to think that things must mot have been that hot. Now here we are and they hope to partner by years end. I really hope this is the case, but I have lost confidence.
GLTA
I have been in this stock since Sept 2012, not nearly as long as many but long enough to see many other investments greatly out perform this one.
Since that time, there have been many positive developments, Phase III, Fast Track, to name a few. But I don't feel that the share price is going anywhere until we partner. Many are now hanging on the words of SK that they will partner by the end of the year. I hope so, be he said that last year also.
I still hold a 25k shares.
GLTA
PPHM is most certainly going to go to the moon soon as I have sold over 100k shares in the past few days. Im still long but with a much smaller position.
GLTA
Venaxis filed for FDA clearance on March 31st. A response should be forthcoming by the end of this month.
I'm long PPHM but thought this article was worth reading just to keep things in perspective:
The Seven Deadly Sins of Biotech Investing:
1. Listen intently to all conference calls and analyst meetings because management can be counted on to speak freely and openly about potential pitfalls in the business, ongoing research and clinical trials. Management will also place all drug development programs in the proper industry context, pointing out competitive risks, for example. History teaches that biotech executives rarely spin or otherwise try to promote their stock. On the whole, they are an honest bunch who always place shareholder interests above their own, so it's a waste of time to seek outside, expert perspectives.
2. Find a good Internet message board to discuss how great an investment the biotech stock you just purchased really is. When spending time on this message board, be sure to read closely all posts from those who are the most vocal proponents of the biotech stock you own. These people demonstrate their commitment by never writing anything critical. No one wants to attend a church where the preacher has doubts. The best posters will write at length about how the science behind the biotech stock you own has no rival and will completely change the world we live in. Lucky for you the world does not know this yet; you are one of a select few!
You may safely ignore others who are more critical. It is well known these bashers are paid by hedge funds shorting your biotech stock and are only hanging out on the message board to shake your confidence. Once you sell and the stock drops, these hedge funds will swoop in and buy the stock lower. Don't let them do this! Honestly, if someone is not a true believer why would he be hanging out on a biotech stock message board in the first place? It makes no sense.
3. If/when you do read "outside" material -- best found by looking for links helpfully posted on your favorite Internet biotech stock message board -- be sure to highlight and read again and again those passages confirming your beliefs in the biotech stock you just purchased. If you have time, copy and paste those same passages to your favorite Internet stock message board to show your fellow longs how to conduct proper "DD." By doing this, you will celebrate together the riches to come.
Be careful. Sometimes you will come across information about the biotech stock you just bought which conflicts with your beliefs. When this happens, it's best to either ignore the negative information, or better yet, copy/post to the Internet stock message board with a healthy serving of disgust and ridicule. If you're lucky, the resident expert on the message board will help remind everyone the negative information about the biotech stock you purchased was obviously the work of an uninformed person, a short, a basher or an envious scientific competitors out to spin. It's best to avoid reading actual scientific papers, altogether. They are full of messy details, caveats and are generally too hard to understand. It's much better to learn all you need to know about the science of the biotech stock you just bought from other, more-educated true believers on Internet stock message boards.
4. Company-issued press releases are the best way to stay current and informed on the positive progress being made by the biotech stock you just bought. Don't bother reading SEC filings like 10-Ks, 10-Qs, proxies or registration statements. Like scientific papers, these SEC filings are overly wordy and filled with obtuse numbers and technical jargon. Also, the SEC is well known to be in the back pocket of the hedge funds, which explains why the SEC filings of the biotech stock you just bought are often filled with risk factors and other information used as ammunition by short sellers and bashers.
If you happen to find yourself accidentally reading risk factor statements in SEC filings, remain calm, take a deep breath and remember it's all boiler plate language. Everything you need to know about the biotech stock you just bought can be found in the company-issued press releases -- and those don't contain risk statements!
5. The strength of the intellectual property of the biotech stock you just bought is best determined by counting the number of patents and patent applications. If this number is uncomfortably low, it's okay to give the company extra credit for thinking about filing a patent, or even just mentioning the word "patent" on a conference call or in a press release. If the management of the biotech stock you just bought never mentions the word "patent," assume they're silent on purpose to keep their groundbreaking scientific discoveries out of the hands of competitors, short sellers and bashers. NEVER read an actual patent application. It's a waste of time and will put you to sleep. ALWAYS assume any patent application mentioned by management will be granted. Competitors' patent applications will be rejected. If in doubt, consult your favorite Internet stock message board for guidance.
6. Keep a close eye on the price of the biotech stock you just bought. The intraday price of your stock tells you almost everything you need to know about the health of your investment. When the price of the stock goes up, the "tutes" -- institutional investors --have discovered your amazing biotech stock and are buying behind you to catch up. A rising stock price also means shorts are scared and covering before the inevitable, massive short squeeze runs them over. Either way, it's always a good idea to buy more of the biotech stock you just bought when the price rises.
In the unlikely event that the biotech stock you just bought falls in value, it's a clear indication of an attack by the shorts. If this happens, check in with your favorite Internet message board. There, you will likely find a link to a negative article written by a reporter or blogger who is clearly getting paid to shill for the short-selling hedge funds. These are bad people trying to steal your shares without doing the proper DD you did. The best way to fight a coordinated short attack is to buy more shares of the biotech stock you just bought. Keep buying.
7. Now that you've bought your biotech stock, it's not necessary to sell it ever, even if your original investment thesis plays out. Everybody knows a buy-and-hold strategy is best. Resist the temptation to sell just because new information has come to light, particularly if that news is negative. Only losers and weak hands sell when the thesis they bought into doesn't pan out. Winners simply change their thesis and buy more! Also, selling a biotech stock shows disrespect to all those patients with terminal illnesses who will otherwise be cured.
I never suggested the Dr Brekken would pretend to be anyone. Anyway, I said it half jokingly, no need to be so sensitive. Good luck
Perhaps so, but your post implies that you know otherwise. Care to enlighten us?
Your posts are clear, well thought out, enthusiastic, and demonstrate a keen ability to simplify otherwise very complicated processes.
Welcome to the ihub board Dr. Brekken!
LOL, agreed
They did say that, but the emphasis in this amendment was *clearly* on the swapping of the A and B arms.
I agree that the emphasis was on the swapping of the A and B arms, I also agree that this might be easier to prove.
My disagreement was with Ex's inference that one could then assume the following to be true.
Now placebo trended better in PFS against both arms, and was better (P<.05) against either 1mg or the 2 bavi arms
I disagree.
The complaint goes on to say that "CSM committed other labeling and distribution errors affecting the A and B arms beyond the swap of the A and B arms"
Question for the board.
On page 8, Peregrine states that they "did not reasonably discover until on or about September 20, 2012 that CSM negligently failed to fulfill those duties"
Would they not want to commit to saying that they gained knowledge on Sept. 20th or 21st for that matter? It seems that adding "on or about" indicates that they don't want to be bound to a specific date. Is this because of the ongoing class action suits?
Yes, thanks!
I just did, we are both correct. The reference to "she" is on page 9, not page 8 as you stated. Anyway, my apologies.
There is no reference to "she" in the complaint and you shouldn't quote something that does not exist.
Thanks! No need to apologize, it is very generous of you to take the time to post this information.
Thank you for posting this, however, page 7 is missing. Could you also post page 7? Thanks!
bid 2.26 ask 2.35
The odd details that you catch are remarkable. I very much enjoy your posts! Yes, they used to be in red, yet another strange coincidence in your observations.
GLTA
I for one have continued to add to my position and have more shares then ever. Interesting times for PPHM. No matter what games are being played, I will give up my shares when they peel my cold dead hands from around them.
GLTA
I for one slept like a baby last night.
I woke up every two hours crying.
Should be a great day for all longs!
I'm very sorry for your loss CJ, deepest sympathies!
I agree with Gull, keep up the good work Chris. I don't doubt that Dr. Thorpe said that Bavi will be approved. Dr. Brekken said the same to me at last years ASM.
GLTA
I was just going to post the same thing
If I felt that way about mgmt, I would be very frustrated.
Carlton Johnson is not the CEO
Funny how quiet you have been. Not a single post during the run up over the past few days. Now we have a down day and here you are.
I believe that we see an EOD surge and news on Tuesday morning.
GLTA
LOL Love the video
Im not sure we can eat the squirrels yet but I do believe that we will close over $2 tomorrow
GLTA
I agree that there will be a PR Monday morning but I think it will be about positive results from the Liver IST. The estimated completion date is December 2013.
http://www.clinicaltrials.gov/ct2/show/NCT01264705?term=bavituximab&rank=8
However, as someone pointed out recently, it seems odd that the status is showing unknown because information hasn't been verified lately.
GLTA
I did read it and re posted the statement and it still isn't clear to me. Perhaps I need another glass of wine.
GLTA
You left out part of the statement, it reads:
We continue our development of PGN650 and looking to move Cotara again into Phase III. Because of all the activities surrounding bavituximab and basically, the startup of the Phase III study, we've determined that we will only initiate that Phase III study in conjunction with a partner, so really pushing this partnering discussion as quickly as we can to move this program into hopefully, the final phase of clinical development towards commercialization.
As PPHMVERYLONG just posted. Cotara will only go into phase III with a partner. Bavi will begin phase III with or without a partner. They have stated this many times.
GLTA